References
- Kaplon H, Reichert JM. Antibodies to watch in 2019. MAbs. 2019;11:219–28. doi:https://doi.org/10.1080/19420862.2018.1556465.
- Goulet DR, Atkins WM. Considerations for the design of antibody-based therapeutics. J Pharm Sci. 2019.
- Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018;11:156–64. doi:https://doi.org/10.1016/j.conctc.2018.08.001.
- Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–15. doi:https://doi.org/10.1038/nrd1470.
- Tomar DS, Singh SK, Li L, Broulidakis MP, Kumar S. In silico prediction of diffusion interaction parameter (kD), a key indicator of antibody solution behaviors. Pharm Res. 2018;35(10):193. doi: https://doi.org/10.1007/s11095-018-2466-6.
- Neergaard MS, Kalonia DS, Parshad H, Nielsen AD, Møller EH. Van de Weert M. Viscosity of high concentration protein formulations of monoclonal antibodies of the IgG1 and IgG4 subclass - Prediction of viscosity through protein-protein interaction measurements. Eur J Pharm Sci. 2013;49:400–10. doi:https://doi.org/10.1016/j.ejps.2013.04.019.
- Jarasch A, Koll H, Regula JT, Bader M, Papadimitriou A, Kettenberger H. Developability assessment during the selection of novel therapeutic antibodies. J Pharm Sci. 2015;104:1885–98. doi:https://doi.org/10.1002/jps.24430.
- Yang X, Xu W, Dukleska S, Benchaar S, Mengisen S, Antochshuk V, Cheung J, Mann L, Babadjanova Z, Rowand J, et al. Developability studies before initiation of process development: improving manufacturability of monoclonal antibodies. MAbs. 2013;5:787–94. doi:https://doi.org/10.4161/mabs.25269.
- Jain T, Sun T, Durand S, Hall A, Houston NR, Nett JH, Sharkey B, Bobrowicz B, Caffry I, Yu Y, et al. Biophysical properties of the clinical-stage antibody landscape. Proc Natl Acad Sci U S A. 2017;114:944–49. doi:https://doi.org/10.1073/pnas.1616408114.
- Xu Y, Wang D, Mason B, Rossomando T, Li N, Liu D, Cheung JK, Xu W, Raghava S, Katiyar A, et al. Structure, heterogeneity and developability assessment of therapeutic antibodies. MAbs. 2019;(11):239–64. doi:https://doi.org/10.1080/19420862.2018.1553476.
- Lauer TM, Agrawal NJ, Chennamsetty N, Egodage K, Helk B, Trout BL. Developability index: A rapid in silico tool for the screening of antibody aggregation propensity. J Pharm Sci. 2012;101:102–15. doi:https://doi.org/10.1002/jps.22758.
- Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. Prediction of aggregation prone regions of therapeutic proteins. J Phys Chem B. 2010;114:6614–24. doi:https://doi.org/10.1021/jp911706q.
- Agrawal NJ, Helk B, Kumar S, Mody N, Sathish HA, Samra HS, Buck PM, Li L, Trout BL. Computational tool for the early screening of monoclonal antibodies for their viscosities. MAbs. 2016;8:43–48. doi:https://doi.org/10.1080/19420862.2015.1099773.
- Seeliger D, Schulz P, Litzenburger T, Spitz J, Hoerer S, Blech M, Enenkel B, Studts JM, Garidel P, Karow AR. Boosting antibody developability through rational sequence optimization. MAbs. 2015;7:505–15. doi:https://doi.org/10.1080/19420862.2015.1017695.
- Obrezanova O, Arnell A, De La Cuesta RG, Berthelot ME, Gallagher TRA, Zurdo J, Stallwood Y. Aggregation risk prediction for antibodies and its application to biotherapeutic development. MAbs. 2015;7:352–63. doi:https://doi.org/10.1080/19420862.2015.1007828.
- van der Kant R, Karow-Zwick AR, Van Durme J, Blech M, Gallardo R, Seeliger D, Aßfalg K, Baatsen P, Compernolle G, Gils A, et al. Prediction and reduction of the aggregation of monoclonal antibodies. J Mol Biol. 2017;429:1244–61. doi:https://doi.org/10.1016/j.jmb.2017.03.014.
- Lu X, Nobrega RP, Lynaugh H, Jain T, Barlow K, Boland T, Sivasubramanian A, Vásquez M, Xu Y. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. MAbs. 2019;11:45–57. doi:https://doi.org/10.1080/19420862.2018.1548233.
- Xu A, Kim HS, Estee S, Viajar S, Galush WJ, Gill A, Hötzel I, Lazar GA, McDonald P, Andersen N, et al. Susceptibility of antibody CDR residues to chemical modifications can be revealed prior to antibody humanization and aid in the lead selection process. Mol Pharm. 2018;15:4529–37. doi:https://doi.org/10.1021/acs.molpharmaceut.8b00536.
- Jain T, Boland T, Lilov A, Burnina I, Brown M, Xu Y, Vásquez M. Prediction of delayed retention of antibodies in hydrophobic interaction chromatography from sequence using machine learning. Bioinformatics. 2017;33:3758–66. doi:https://doi.org/10.1093/bioinformatics/btx519.
- Hanke AT, Klijn ME, Verhaert PDEM, van der Wielen LAM, Ottens M, Eppink MHM. van de Sandt EJAX. Prediction of protein retention times in hydrophobic interaction chromatography by robust statistical characterization of their atomic-level surface properties. Biotechnol Prog. 2016;32:372–81. doi:https://doi.org/10.1002/btpr.2219.
- Lefranc MP, Giudicelli V, Kaas Q, Duprat E, Jabado-Michaloud J, Scaviner D, Ginestoux C, Clément O, Chaume D, Lefranc G. IMGT, the international ImMunoGeneTics information system®. Nucleic Acids Res. 2005 Jan 1;33(Database issue):D593–7.
- Milstein C. The hybridoma revolution: an offshoot of basic research. BioEssays. 1999;21:966–73. doi:https://doi.org/10.1002/(SICI)1521-1878(199911)21:11<966::AID-BIES9>3.0.CO;2-Z.
- Lee EC, Owen M. The application of transgenic mice for therapeutic antibody discovery. Methods Mol Biol. 2012;901:137–48.
- Wang W. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm. 2005;289:1–30. doi:https://doi.org/10.1016/j.ijpharm.2004.11.014.
- Philo J, Arakawa T. Mechanisms of Protein Aggregation. Curr Pharm Biotechnol. 2009;10:348–51. doi:https://doi.org/10.2174/138920109788488932.
- Cromwell MEM, Hilario E, Jacobson F. Protein aggregation and bioprocessing. Aaps J. 2006 Sep 15;8(3):E572–9.
- Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies revealed by charge-sensitive methods. Curr Pharm Biotechnol. 2008;9:468–81. doi:https://doi.org/10.2174/138920108786786402.
- Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J. Heterogeneity of monoclonal antibodies. J Pharm Sci. 2008;97:2426–47. doi:https://doi.org/10.1002/jps.21180.
- Hebditch M, Roche A, Curtis RA, Warwicker J. Models for antibody behavior in hydrophobic interaction chromatography and in self-association. J Pharm Sci. 2019;108:1434–41. doi:https://doi.org/10.1016/j.xphs.2018.11.035.
- Kelly RL, Sun T, Jain T, Caffry I, Yu Y, Cao Y, Lynaugh H, Brown M, Vásquez M, Dane Wittrup K, et al. High throughput cross-interaction measures for human IgG1 antibodies correlate with clearance rates in mice. MAbs. 2015;7:770–77. doi:https://doi.org/10.1080/19420862.2015.1043503.
- Jacobitz AW, Dykstra AB, Spahr C, Agrawal NJ. Effects of buffer composition on site-specific glycation of lysine residues in monoclonal antibodies. J Pharm Sci. 2019 Jan;109(1):293–300. doi: https://doi.org/10.1016/j.xphs.2019.05.025. Epub 2019 May 29.
- Goyon A, Excoffier M, Janin-Bussat MC, Bobaly B, Fekete S, Guillarme D, Beck A. Determination of isoelectric points and relative charge variants of 23 therapeutic monoclonal antibodies. J Chromatogr B Anal Technol Biomed Life Sci. 2017;1065–1066:119–28. doi:https://doi.org/10.1016/j.jchromb.2017.09.033.
- Breitsprecher D, Glücklich N, Hawe A, Menzen T Comparison of nanoDSF and µDSC for thermal stability assessment during biopharmaceutical formulation development [Internet]. 2006 [cited 2020 Jan 27]; Available from: https://resources.nanotempertech.com/application-notes/application-note-nt-pr-006-dsc-nanodsf-comparison
- Estep P, Caffry I, Yu Y, Sun T, Cao Y, Lynaugh H, Jain T, Vásquez M, Tessier PM, Xu Y. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies. MAbs. 2015;7:553–61. doi:https://doi.org/10.1080/19420862.2015.1016694.
- Liu Y, Caffry I, Wu J, Geng SB, Jain T, Sun T, Reid F, Cao Y, Estep P, Yu Y, et al. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy. MAbs. 2014;6:483–92. doi:https://doi.org/10.4161/mabs.27431.
- Alam ME, Geng SB, Bender C, Ludwig SD, Linden L, Hoet R, Tessier PM. Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with high colloidal stability. Mol Pharm. 2018;15:150–63. doi:https://doi.org/10.1021/acs.molpharmaceut.7b00779.
- Tomar DS, Li L, Broulidakis MP, Luksha NG, Burns CT, Singh SK, Kumar S. In-silico prediction of concentration-dependent viscosity curves for monoclonal antibody solutions. MAbs. 2017;9:476–89. doi:https://doi.org/10.1080/19420862.2017.1285479.
- Dani B, Platz R, Tzannis ST. High concentration formulation feasibility of human immunoglobulin G for subcutaneous administration. J Pharm Sci. 2007;96:1504–17. doi:https://doi.org/10.1002/jps.20508.
- Hofmann M, Winzer M, Weber C, Gieseler H. Limitations of polyethylene glycol-induced precipitation as predictive tool for protein solubility during formulation development. J Pharm Pharmacol. 2018;70:648–54. doi:https://doi.org/10.1111/jphp.12699.
- Sankar K, Hoi KH, Yin Y, Ramachandran P, Andersen N, Hilderbrand A, McDonald P, Spiess C, Zhang Q. Prediction of methionine oxidation risk in monoclonal antibodies using a machine learning method. MAbs. 2018;10:1281–90. doi:https://doi.org/10.1080/19420862.2018.1518887.
- Robinson NE, Robinson AB. Prediction of protein deamidation rates from primary and three-dimensional structure. Proc Natl Acad Sci U S A. 2001;98:4367–72. doi:https://doi.org/10.1073/pnas.071066498.
- Hao P, Adav SS, Gallart-Palau X, Sze SK. Recent advances in mass spectrometric analysis of protein deamidation. Mass Spectrom Rev. 2017 Nov;36(6):677–92. Epub 2016 Jan 13. doi:https://doi.org/10.1002/mas.21491.
- Lechner A, Giorgetti J, Gahoual R, Beck A, Leize-Wagner E, François YN. Insights from capillary electrophoresis approaches for characterization of monoclonal antibodies and antibody drug conjugates in the period 2016–2018. J Chromatogr B Anal Technol Biomed Life Sci. 2019;1122–1123:1–17. doi:https://doi.org/10.1016/j.jchromb.2019.05.014.
- Giorgetti J, D’Atri V, Canonge J, Lechner A, Guillarme D, Colas O, Wagner-Rousset E, Beck A, Leize-Wagner E, François YN. Monoclonal antibody N-glycosylation profiling using capillary electrophoresis – mass spectrometry: assessment and method validation. Talanta. 2018;178:530–37. doi:https://doi.org/10.1016/j.talanta.2017.09.083.
- Azadi P, Heiss C. Mass spectrometry of N-linked glycans. Methods Mol Biol. 2009;534:37–51. doi:https://doi.org/10.1007/978-1-59745-022-5_3.
- Miyanabe K, Yamashita T, Abe Y, Akiba H, Takamatsu Y, Nakakido M, Hamakubo T, Ueda T, Caaveiro JMM, Tsumoto K. Tyrosine sulfation restricts the conformational ensemble of a flexible peptide, strengthening the binding affinity for an antibody. Biochemistry. 2018;57:4177–85. doi:https://doi.org/10.1021/acs.biochem.8b00592.
- Banks DD, Gadgil HS, Pipes GD, Bondarenko PV, Hobbs V, Scavezze JL, Kim J, Jiang XR, Mukku V, Dillon TM. Removal of cysteinylation from an unpaired sulfhydryl in the variable region of a recombinant monoclonal IgG1 antibody improves homogeneity, stability, and biological activity. J Pharm Sci. 2008;97:775–90. doi:https://doi.org/10.1002/jps.21014.
- Mason M, Sweeney B, Cain K, Stephens P, Sharfstein ST. Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in chinese hamster ovary cells. Biotechnol Prog. 2012;28:846–55. doi:https://doi.org/10.1002/btpr.1542.
- Benner SW, Welsh JP, Rauscher MA, Pollard JM. Prediction of lab and manufacturing scale chromatography performance using mini-columns and mechanistic modeling. J Chromatogr A. 2019;1593:54–62. doi:https://doi.org/10.1016/j.chroma.2019.01.063.
- He F, Woods CE, Trilisky E, Bower KM, Litowski JR, Kerwin BA, Becker GW, Narhi LO, Razinkov VI. Screening of monoclonal antibody formulations based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J Pharm Sci. 2011;100:1330–40. doi:https://doi.org/10.1002/jps.22384.
- Alfthan K. Surface plasmon resonance biosensors as a tool in antibody engineering. In: biosensors and Bioelectronics. Elsevier Sci Ltd. 1998 Sep 15;13(6):653–63.
- Xu Y, Roach W, Sun T, Jain T, Prinz B, Yu TY, Torrey J, Thomas J, Bobrowicz P, Vásquez M, et al. Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: A FACS-based, high-throughput selection and analytical tool. Protein Eng Des Sel. 2013;26:663–70. doi:https://doi.org/10.1093/protein/gzt047.
- Hötzel I, Theil FP, Bernstein LJ, Prabhu S, Deng R, Quintana L, Lutman J, Sibia R, Chan P, Bumbaca D, et al. A strategy for risk mitigation of antibodies with fast clearance. MAbs. 2012;4:753–60. doi:https://doi.org/10.4161/mabs.22189.
- Schoch A, Kettenberger H, Mundigl O, Winter G, Engert J, Heinrich J, Emrich T. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics. Proc Natl Acad Sci U S A. 2015;112:5997–6002. doi:https://doi.org/10.1073/pnas.1408766112.
- Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol. 2010;10:345–52. doi:https://doi.org/10.1038/nri2747.
- Avery LB, Wade J, Wang M, Tam A, King A, Piche-Nicholas N, Kavosi MS, Penn S, Cirelli D, Kurz JC, et al. Establishing in vitro in vivo correlations to screen monoclonal antibodies for physicochemical properties related to favorable human pharmacokinetics. MAbs. 2018;10:244–55. doi:https://doi.org/10.1080/19420862.2017.1417718.
- Kizhedath A, Karlberg M, Glassey J. Cross-Interaction Chromatography-Based QSAR Model for Early-Stage Screening to Facilitate Enhanced Developability of Monoclonal Antibody Therapeutics. Biotechnol J. 2019 2019 Aug;14(8):e1800696. doi:https://doi.org/10.1002/biot.201800696. Epub 2019 Apr 17.Biotechnol J.
- Raybould MIJ, Marks C, Krawczyk K, Taddese B, Nowak J, Lewis AP, Bujotzek A, Shi J, Deane CM. Five computational developability guidelines for therapeutic antibody profiling. Proc Natl Acad Sci U S A. 2019;116:4025–30. doi:https://doi.org/10.1073/pnas.1810576116.
- Jia L, Sun Y. Protein asparagine deamidation prediction based on structures with machine learning methods. PLoS One. 2017 Jul 21;12(7):e0181347. doi:https://doi.org/10.1371/journal.pone.0181347. eCollection 2017.
- Shan L, Mody N, Sormani P, Rosenthal KL, Damschroder MM, Esfandiary R. Developability assessment of engineered monoclonal antibody variants with a complex self-association behavior using complementary analytical and in silico tools. Mol Pharm. 2018;15:5697–710.
- Tomar DS, Kumar S, Singh SK, Goswami S, Li L. Molecular basis of high viscosity in concentrated antibody solutions: strategies for high concentration drug product development. MAbs. 2016;8:216–28. doi:https://doi.org/10.1080/19420862.2015.1128606.
- Fekete S, Veuthey JL, Beck A, Guillarme D. Hydrophobic interaction chromatography for the characterization of monoclonal antibodies and related products. J Pharm Biomed Anal. 2016;130:3–18. doi:https://doi.org/10.1016/j.jpba.2016.04.004.
- Sharma VK, Patapoff TW, Kabakoff B, Pai S, Hilario E, Zhang B, Li C, Borisov O, Kelley RF, Chorny I, et al. In silico selection of therapeutic antibodies for development: viscosity, clearance, and chemical stability. Proc Natl Acad Sci U S A. 2014;111:18601–06. doi:https://doi.org/10.1073/pnas.1421779112.
- Thiagarajan G, Semple A, James JK, Cheung JK, Shameem M. A comparison of biophysical characterization techniques in predicting monoclonal antibody stability. MAbs. 2016;8:1088–97. doi:https://doi.org/10.1080/19420862.2016.1189048.
- E-Notebook. [software]. Waltham (MA (USA)): PerkinElmer, Inc.2019.
- TIBCO Spotfire. Version 10.3.2 [software]. Palo Alto (CA (USA)): TIBCO Software Inc. 2019.
- JMP Software Suite. Version 15 [software]. Cary (NC (USA)): SAS Institute Inc. 2019.
- Heads JT, Adams R, D’Hooghe LE, Page MJT, Humphreys DP, Popplewell AG, Lawson AD, Henry AJ. Relative stabilities of IgG1 and IgG4 Fab domains: influence of the light-heavy interchain disulfide bond architecture. Protein Sci. 2012;21:1315–22. doi:https://doi.org/10.1002/pro.2118.
- Neergaard MS, Nielsen AD, Parshad H, Van De Weert M. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass. J Pharm Sci. 2014;103:115–27. doi:https://doi.org/10.1002/jps.23788.
- Kowalski JM, Parekh RN, Wittrup KD. Secretion efficiency in Saccharomyces cerevisiae of bovine pancreatic trypsin inhibitor mutants lacking disulfide bonds is correlated with thermodynamic stability. Biochemistry. 1998;37:1264–73. doi:https://doi.org/10.1021/bi9722397.
- Schaefer JV, Plückthun A. Transfer of engineered biophysical properties between different antibody formats and expression systems. Protein Eng Des Sel. 2012;25:485–505. doi:https://doi.org/10.1093/protein/gzs039.
- Zhang L, Shi S, Antochshuk V. Closing the gap: counting and sizing of particles across submicron range by flow cytometry in therapeutic protein products. J Pharm Sci. 2017;106:3215–21. doi:https://doi.org/10.1016/j.xphs.2017.06.007.
- Mian IS, Bradwell AR, Olson AJ. Structure, function and properties of antibody binding sites. J Mol Biol. 1991;217:133–51. doi:https://doi.org/10.1016/0022-2836(91)90617-F.
- Samanta U, Pal D, Chakrabarti P. Packing of aromatic rings against tryptophan residues in proteins. Acta Crystallogr Sect D Biol Crystallogr. 1999;55:1421–27. doi:https://doi.org/10.1107/S090744499900726X.
- Makwana KM, Mahalakshmi R. Implications of aromatic-aromatic interactions: from protein structures to peptide models. Protein Sci. 2015;24:1920–33. doi:https://doi.org/10.1002/pro.2814.
- Reason AJ, Weiskopf A, Rathore A. Defining critical quality attributes for monoclonal antibody therapeutic products. BioPharm Int. 2014;27(7):34–43.
- Alt N, Zhang TY, Motchnik P, Taticek R, Quarmby V, Schlothauer T, Beck H, Emrich T, Harris RJ. Determination of critical quality attributes for monoclonal antibodies using quality by design principles. Biologicals. 2016;44:291–305. doi:https://doi.org/10.1016/j.biologicals.2016.06.005.
- Zurdo J, Arnell A, Obrezanova O, Smith N, R GDLC, Gallagher TRA, Michael R, Stallwood Y, Ekblad C, Abrahmsén L, et al. Early implementation of QbD in biopharmaceutical development: A practical example. Biomed Res Int. 2015;2015. doi:https://doi.org/10.1155/2015/605427.
- Saxena V, Panicucci R, Joshi Y, Garad S. Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates. J Pharm Sci. 2009;98:1962–79. doi:https://doi.org/10.1002/jps.21592.
- Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. MAbs. 2015;7:9–14. doi:https://doi.org/10.4161/19420862.2015.989042.
- Mirasol F Taking therapeutic antibodies to the next level [Internet]. BioPharm Int.2019 [cited 2020 Jan 27];:14–16. Available from: http://www.biopharminternational.com/taking-therapeutic-antibodies-next-level
- Molecular Operating Environment (MOE). Version 2019.0102 [software]. Montreal (Canada): Chemical Computing Group ULC. 2019.
- Maier JKX, Labute P. Assessment of fully automated antibody homology modeling protocols in molecular operating environment. Proteins Struct Funct Bioinforma. 2014;82:1599–610. doi:https://doi.org/10.1002/prot.24576.
- Labute P. LowModeMD - Implicit low-mode velocity filtering applied to conformational search of macrocycles and protein loops. J Chem Inf Model. 2010;50:792–800. doi:https://doi.org/10.1021/ci900508k.
- Hebditch M, Warwicker J. Web-based display of protein surface and pH-dependent properties for assessing the developability of biotherapeutics. Sci Rep. 2019;9:1969. doi:https://doi.org/10.1038/s41598-018-36950-8.